News on lab-developed tests and emerging diagnostic technologies.
Over the next month the company plans to expand its preconception screening test, which it launched widely earlier this year, by adding about 90 X-linked disorders.
Researchers are working with the Australian Ministry of Health to commercialize a diagnostic test that employs the biomarker and could be available within two to five years.
The distribution deal comes less than a month after the firm announced that the FDA cleared for marketing the revogene instrument along with the GenePOC GBS LB assay.
SOL will help Personal Genomics to further develop its research projects and implement its new facility dedicated to DNA sequencing.
The deal with Aetna includes coverage for Interpace's ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier.
